Sale of 7.7 g of Radium-226 for medical applications
Value
Estimated—
Awarded—
CPV codes
09343000 Petroleum, fuel, electricity & energyDescription
The European Commission, Joint Research Centre (JRC) in Karlsruhe (Germany) plans to sell approximately 7.7 grams of Radium-226 (Ra-226), a valuable resource from its our strategic inventory utilised for cutting-edge research and development in nuclear medical applications. This includes applications in the production of Actinium-225 (Ac-225) for the use of targeted alpha therapy. Following a surge of demand for Ac-225, Ra-226 material serves as a crucial source material for producing it as well as other valuable medical radioisotopes, such as Lead-212 (Pb-212). With a growing demand and limited supply for Ra-226, the JRC Karlsruhe wants to contribute to the medical isotope supply chain. The expertise along with the state-of-the-art assets at JRC Karlsruhe, equips it to contribute effectively to this critical field. This sale is meant to bolster the availability of Ra-226 for medical applications and further the advancement of nuclear medicine.
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-05-26 | Supply of an innert glovebox chain for the JRC Karlsruhe | European Commission, DG JRC - Joint Research Centre DE | 87% |
| 2026-05-06 | Provision of analytical measurements | European Commission, DG JRC - Joint Research Centre BE | 87% |
| 2026-06-30 | Supply and preparation for nuclear environment of an ONH gas analyser in metals | European Commission, DG JRC - Joint Research Centre DE | 87% |
| 2026-06-15 | Supply and maintenance of Radiation Portal Monitoring System | European Commission, DG JRC - Joint Research Centre DE | 86% |
| 2026-06-30 | Evidence reviews for the European Commission Initiatives on cancer screening and care | European Commission, DG JRC - Joint Research Centre IT | 86% |
| 2026-06-17 | Procurement of medicines for 2026 Biological therapy | University clinic of radiotherapy and oncology MK | 86% |